GABRA5

Chr 15AD

gamma-aminobutyric acid type A receptor subunit alpha5

Also known as: DEE79, EIEE79

GABA is the major inhibitory neurotransmitter in the mammalian brain where it acts at GABA-A receptors, which are ligand-gated chloride channels. Chloride conductance of these channels can be modulated by agents such as benzodiazepines that bind to the GABA-A receptor. At least 16 distinct subunits of GABA-A receptors have been identified. Transcript variants utilizing three different alternative non-coding first exons have been described. [provided by RefSeq, Jul 2008]

OMIMResearchGenerating clinical summary…
MultiplemechanismADLOEUF 0.371 OMIM phenotype
Clinical SummaryGABRA5
Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.91). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
6 unique Pathogenic / Likely Pathogenic· 74 VUS of 132 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?
0.37LOEUF
pLI 0.905
Z-score 3.62
OE 0.14 (0.070.37)
Highly constrained

More LoF-intolerant than ~75% of genes

Missense Constraint?
3.23Z-score
OE missense 0.46 (0.390.53)
127 obs / 278.8 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios?
LoF OE?0.14 (0.070.37)
00.351.4
Missense OE?0.46 (0.390.53)
00.61.4
Synonymous OE?1.03
01.21.6
LoF obs/exp: 3 / 20.8Missense obs/exp: 127 / 278.8Syn Z: -0.25

This gene — mechanism propensity

DN
0.6937th %ile
GOF
0.75top 25%
LOF
0.4430th %ile

This gene has evidence for multiple mechanisms of pathogenicity (dominant-negative, gain-of-function and loss-of-function). The Badonyi & Marsh model scores gain-of-function highest among its predictions, but genomic evidence (constraint, ClinVar variant spectrum, and literature) most strongly supports dominant-negative. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

DNprediction above median · 1 literature citation
GOFprediction above median
LOFLOEUF 0.37

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

DNFurthermore, mutant a5(S413F)HA subunits had a dominant negative effect by decreasing the trafficking of partnering b3 (0.65 ± 0.06, P = 0.0003, n = 4) and g2 (0.65 ± 0.06, P = 0.0106, n = 4) subunits to the surface (Fig. 3C, middle and bottom). Mutant a5(S413F)HA subunits had a dominant negative ef1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 31056671

ClinVar Variant Classifications

132 submitted variants in ClinVar

Classification Summary

Pathogenic3
Likely Pathogenic3
VUS74
Likely Benign37
Benign12
Conflicting1
3
Pathogenic
3
Likely Pathogenic
74
VUS
37
Likely Benign
12
Benign
1
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
2
1
0
3
Likely Pathogenic
0
3
0
0
3
VUS
5
65
3
1
74
Likely Benign
0
6
5
26
37
Benign
0
1
5
6
12
Conflicting
1
Total5771433130

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

305 pathogenic / likely-pathogenic (of 312) ClinVar copy-number / structural variants overlap GABRA5 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

GABRA5 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →